Peptide Intelligence · GLP-1
Retatrutide
Also: LY3437943
An investigational triple agonist (GLP-1, GIP and glucagon receptors) in phase 3 trials for obesity and type 2 diabetes.
Approval status
Investigational (in trials)
Not approved for any indication. In clinical trials.
Compounding status
Sold as research-use-only · unapproved drug
Any product sold outside a clinical trial is an unapproved drug with no quality assurance. It cannot legally be compounded.
Evidence grade
B · Small or uncontrolled human studies
Phase 2 RCT data published; phase 3 ongoing. Long-term safety not established.
If you already have a vial
Products sold as research-use-only are unapproved drugs. Nothing required the seller to verify identity, purity, sterility or concentration. That is the practical risk, more than the compound itself. Worth discussing with your clinician before you continue, and worth logging so your labs can be read against it.
Known risks and label warnings
- Unknown long-term safety
- GI effects similar to other incretin drugs
- Heart-rate increase observed in phase 2
Interactions people ask about
- Unknown
What people often measure
Framed as things to discuss with your clinician, not a protocol.
- Only under trial protocol
Questions for your clinician
- Is there a clinical trial I could join?
Get the full report by email
- The Retatrutide status card, monitoring list and clinician questions, printable
- The pre-therapy baseline checklist: what people commonly measure before starting any injectable
- A note the next time FDA or HHS acts on this compound
Wellness guidance only, not medical advice. We never sell or dispense medication.
Sources and review
Status as of 2026-09-02. Reviewed 2026-09-02 by Curtis Holder (product); clinical review pending; next review due 2026-12-01. Regulatory status changes; we update this page after each FDA or HHS action. Wellness guidance only, not medical advice. Med.xyz does not sell, prescribe or recommend any compound.